<?xml version="1.0"?>

<document>
	<title>Immunochemical quantitation of 18 proteins in sera from patients
   with cystic fibrosis: concentrations correlated to class of
   fibroblast metachromasia, clinical and radiological lung symptoms.</title>

	<author>Weeke-B.</author>
	<author>Flensborg-E-W.</author>
	<author>Jacobsen-L.</author>
	<author>Jorgensen-B-A.</author>
	<author>Lykkegaard-E.</author>
	<author>Hoiby-N.</author>

	<source>Dan-Med-Bull. 1976 Jun. 23(3). P 155-60.</source>

	<abstract>Sera from 32 patients with cystic fibrosis classified according to
   fibroblast metachromasia into three classes have been analysed
   immunochemically for the concentrations of 18 serum proteins.  In
   addition, the clinical and radiological status of the lungs were
   evaluated, using two scoring systems.  Eleven of 16 serum proteins
   differed from the values of a thousand-donor serum pool.  The most
   pronounced differences from the control sera were elevated
   acute-phase proteins, notably haptoglobin, alpha1-antichymotrypsin,
   IgG, and IgA, and low serum albumin and alpha2-HS-glycoprotein.
   Patients from metachromatic class III presented the most pronounced
   rise in acute-phase proteins and, furthermore, significantly
   decreased complement C3 and IgM, IgG and IgA were normal in class III
   patients.  These differences from the control sera possibly reflect
   inflammatory tissue damage involving immune reactions.  The clinical
   score was positively correlated to the radiologic score, and both
   these scores were positively correlated to the concentrations of
   eight and seven, respectively, of the serum proteins, and negatively
   correlated to three of the serum proteins.  Based upon the
   correlations between the scores and the concentrations of some of the
   serum proteins, it is recommended that longitudinal prospective
   studies follow individual patients for the concentrations in serum of
   haptoglobin, albumin, IgA, IgG, C3, and, eventually, IgM and
   alpha1-antichymotrypsin.  The present results suggest that these
   serum proteins will yield valuable information as regards prognosis
   and therapy of the lung disease in CF.</abstract>

	<majorsubject>BLOOD-PROTEINS: an</majorsubject>
	<majorsubject>CYSTIC-FIBROSIS: bl</majorsubject>
	<majorsubject>FIBROBLASTS: me</majorsubject>

	<minorsubject>ADOLESCENCE</minorsubject>
	<minorsubject>ADULT</minorsubject>
	<minorsubject>CHILD</minorsubject>
	<minorsubject>CHILD-PRESCHOOL</minorsubject>
	<minorsubject>ENGLISH-ABSTRACT</minorsubject>
	<minorsubject>FEMALE</minorsubject>
	<minorsubject>FLUORESCENT-ANTIBODY-TECHNIC</minorsubject>
	<minorsubject>HUMAN</minorsubject>
	<minorsubject>IMMUNOELECTROPHORESIS</minorsubject>
	<minorsubject>LUNG-DISEASES: bl</minorsubject>
	<minorsubject>MALE</minorsubject>

	<reference>001   BELFRAGE S            ACTA MED SCAND SUPPL           173     5 963</reference>
	<reference>002   BERG T                ACTA PAEDIATR SCAND             58   513 969</reference>
	<reference>003   BROGAN TD             THORAX                          30    72 975</reference>
	<reference>004   BUCKLEY RH            J CLIN INVEST                   55   157 975</reference>
	<reference>005   CONOVER JH            LIFE SCI                        14   253 974</reference>
	<reference>006   CONOVER JH            LANCET                           2  1501 973</reference>
	<reference>007   CONOVER JH            LANCET                           1    47 975</reference>
	<reference>008   DANES BS              J EXP MED                      129   775 969</reference>
	<reference>009   DANES BS              AM J HUM GENET                  23   297 971</reference>
	<reference>010   DANES BS              J EXP MED                      137  1538 973</reference>
	<reference>011   HANN S                LANCET                           2   520 974</reference>
	<reference>012   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973</reference>
	<reference>013   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974</reference>
	<reference>014   HOIBY N               ACTA PAEDIATR SCAND             63   843 974</reference>
	<reference>015   HOIBY N               SCAND J RESPIR DIS              56    38 975</reference>
	<reference>016   LANGGARD H            ACTA PAEDIATR SCAND             57   255 968</reference>
	<reference>017   LIEBERMAN J           LANCET                           1  1230 974</reference>
	<reference>018   LUNDH B               ACTA UNIV LUND II               24     1 965</reference>
	<reference>019   LYKKEGAARD E          DAN MED BULL                    21   232 974</reference>
	<reference>020   LYKKEGAARD E          DAN MED BULL                    21   241 974</reference>
	<reference>021   LYKKEGAARD E          DAN MED BULL                    22   169 975</reference>
	<reference>022   LYKKEGAARD E          DAN MED BULL                    22   175 975</reference>
	<reference>023   LYKKEGAARD E          DAN MED BULL                    22   177 975</reference>
	<reference>024   MCFARLANE H           BR MED J                         1   423 975</reference>
	<reference>025   MULLER HE             DTSCH MED WSCHR                 93   120 968</reference>
	<reference>026   MINCHIN-CLARKE HG     THORAX                          25   423 970</reference>
	<reference>027   NIELSEN HG            CLIN CHIM ACTA                  36   133 972</reference>
	<reference>028   NORMAN AP             PROC EWGCF 2ND ANNU MTG                  971</reference>
	<reference>029   NYMAN M               SCAND J CLIN LAB INVEST SUPPL   39     5 959</reference>
	<reference>030   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975</reference>
	<reference>031   SCHWARTZ RH           AM J DIS CHILD                 111   408 966</reference>
	<reference>032   STROBER W             PEDIATRICS                      43   416 969</reference>
	<reference>033   TANNER JM             ARCH DIS CHILD                  41   613 966</reference>
	<reference>034   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974</reference>
	<reference>035   WEEKE B               ACTA MED SCAND                 192   149 972</reference>
	<reference>036   WEEKE B               THESIS                                 1 973</reference>
	<reference>037   WEEKE B               SCAND J IMMUNOL SUPPL 1          2    37 973</reference>
	<reference>038   WEEKE B               SCAND J IMMUNOL SUPPL 2          1    48 973</reference>

	<citation>1   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     3 977</citation>
	<citation>2   TURNER MW             ARCH DIS CHILD                  53   631 978</citation>
	<citation>3   GOTZ M                EUR J PEDIATR                  127   133 978</citation>
	<citation>4   SCHIOTZ PO            MONOGR PAEDIATR                 10   131 979</citation>
	<citation>5   JAKEL HP              BIOL ZENTRALBL                  98    55 979</citation>
	<citation>6   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981</citation>
	<citation>7   FICK RB               CLIN CHEST MED                   2    91 981</citation>
	<citation>8   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   89   185 981</citation>
	<citation>9   MARGOLIES R           PEDIATR RES                     16   181 982</citation>
	<citation>10   BERNINGER RW          METABOLISM                      31   299 982</citation>
	<citation>11   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982</citation>
	<citation>12   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982</citation>
	<citation>13   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982</citation>
	<citation>14   EMMETT M              PROC SOC EXP BIOL MED          184    74 987</citation>

</document>
